Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion–Positive Intrahepatic Cholangiocarcinoma
Lipika Goyal, Lei Shi, Leah Y. Liu, et al.
Cancer Discovery (2019) Vol. 9, Iss. 8, pp. 1064-1079
Open Access | Times Cited: 321

Showing 1-25 of 321 citing articles:

Biliary tract cancer
Juan W. Valle, Robin Katie Kelley, Bruno Nervi, et al.
The Lancet (2021) Vol. 397, Iss. 10272, pp. 428-444
Closed Access | Times Cited: 670
Systemic therapies for intrahepatic cholangiocarcinoma
Robin Kate Kelley, John Bridgewater, Gregory J. Gores, et al.
Journal of Hepatology (2020) Vol. 72, Iss. 2, pp. 353-363
Open Access | Times Cited: 321
Futibatinib for FGFR2 -Rearranged Intrahepatic Cholangiocarcinoma
Lipika Goyal, Funda Meric‐Bernstam, Antoine Hollebecque, et al.
New England Journal of Medicine (2023) Vol. 388, Iss. 3, pp. 228-239
Open Access | Times Cited: 318
Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance
Melanie A. Krook, Julie W. Reeser, Gabrielle Ernst, et al.
British Journal of Cancer (2020) Vol. 124, Iss. 5, pp. 880-892
Open Access | Times Cited: 256
Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update
Robert Roskoski
Pharmacological Research (2022) Vol. 187, pp. 106552-106552
Open Access | Times Cited: 242
Personalized Medicine: Recent Progress in Cancer Therapy
Valentina Gambardella, Noelia Tarazona, Juan Miguel Cejalvo, et al.
Cancers (2020) Vol. 12, Iss. 4, pp. 1009-1009
Open Access | Times Cited: 223
Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm
Yoshiaki Nakamura, Akihito Kawazoe, Florian Lordick, et al.
Nature Reviews Clinical Oncology (2021) Vol. 18, Iss. 8, pp. 473-487
Closed Access | Times Cited: 211
Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib
Ian M. Silverman, Antoine Hollebecque, Luc Friboulet, et al.
Cancer Discovery (2020) Vol. 11, Iss. 2, pp. 326-339
Open Access | Times Cited: 210
Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors HarboringFGF/FGFRAberrations: A Phase I Dose-Expansion Study
Funda Meric‐Bernstam, Rastislav Bahleda, Cinta Hierro, et al.
Cancer Discovery (2021) Vol. 12, Iss. 2, pp. 402-415
Open Access | Times Cited: 200
Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies
Mihaela Aldea, Fabrice André, Aurélien Marabelle, et al.
Cancer Discovery (2021) Vol. 11, Iss. 4, pp. 874-899
Open Access | Times Cited: 197
Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion
Debyani Chakravarty, Amber M. Johnson, Jeffrey Sklar, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 11, pp. 1231-1258
Open Access | Times Cited: 171
Futibatinib Is a Novel Irreversible FGFR 1–4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors
Hiroshi Sootome, Hidenori Fujita, Kenjiro Ito, et al.
Cancer Research (2020) Vol. 80, Iss. 22, pp. 4986-4997
Open Access | Times Cited: 156
Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions
Michael L. Cheng, Eirini Pectasides, Glenn J. Hanna, et al.
CA A Cancer Journal for Clinicians (2020) Vol. 71, Iss. 2, pp. 176-190
Open Access | Times Cited: 150
Biomarkers for Hepatobiliary Cancers
Jean–Charles Nault, Augusto Villanueva
Hepatology (2020) Vol. 73, Iss. S1, pp. 115-127
Closed Access | Times Cited: 148
Targeting FGFR inhibition in cholangiocarcinoma
Lipika Goyal, Sarinya Kongpetch, Valerie Crolley, et al.
Cancer Treatment Reviews (2021) Vol. 95, pp. 102170-102170
Open Access | Times Cited: 137
Current and emerging therapies for advanced biliary tract cancers
Audrey E. Kam, Ashiq Masood, Rachna T. Shroff
˜The œLancet. Gastroenterology & hepatology (2021) Vol. 6, Iss. 11, pp. 956-969
Closed Access | Times Cited: 120
FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice
Anuhya Kommalapati, Sri Harsha Tella, Mitesh J. Borad, et al.
Cancers (2021) Vol. 13, Iss. 12, pp. 2968-2968
Open Access | Times Cited: 118
FGFR-TKI resistance in cancer: current status and perspectives
Sitong Yue, Yukun Li, Xiaojuan Chen, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 115
Practical considerations in screening for genetic alterations in cholangiocarcinoma
Tanios Bekaii‐Saab, John Bridgewater, Nicola Normanno
Annals of Oncology (2021) Vol. 32, Iss. 9, pp. 1111-1126
Open Access | Times Cited: 108
Cholangiocarcinoma — novel biological insights and therapeutic strategies
Sumera I. Ilyas, Silvia Affò, Lipika Goyal, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 7, pp. 470-486
Open Access | Times Cited: 92
The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer
J.E. Berchuck, Francesco Facchinetti, Daniel DiToro, et al.
Annals of Oncology (2022) Vol. 33, Iss. 12, pp. 1269-1283
Open Access | Times Cited: 86
RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity acrossFGFR2Alterations and Resistance Mutations
Vivek Subbiah, Vaibhav Sahai, Dejan Maglic, et al.
Cancer Discovery (2023) Vol. 13, Iss. 9, pp. 2012-2031
Open Access | Times Cited: 69
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
Masuko Katoh, Yohann Loriot, Giovanni Brandi, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 4, pp. 312-329
Closed Access | Times Cited: 63
Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2
Heike Schönherr, Pelin Ayaz, Alexander M. Taylor, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 6
Open Access | Times Cited: 22
Pemigatinib in previously treated solid tumors with activating FGFR1–FGFR3 alterations: phase 2 FIGHT-207 basket trial
Jordi Rodón, Silvia Damian, Muhammad Furqan, et al.
Nature Medicine (2024) Vol. 30, Iss. 6, pp. 1645-1654
Open Access | Times Cited: 21
Page 1 - Next Page

Scroll to top